Summation
- In the coming months, the program will grow to include additional pathologies and providers outside of the U.
- The RWE Program will expand Summus Laser’s Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
- The program’s initial Circles will collect and analyze real-world evidence on peripheral neuropathy from dozens of providers in the U.
Summus Medical Laser
Summus Medical Laser® has partnered with RegenMed to establish a comprehensive Real-World Evidence Program. The program will support thousands of providers around the world by developing and sharing best practices for improving patient recovery and care. The RWE Program will expand Summus Laser’s Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Summus’ RWE Program
Summus’ RWE Program builds upon recent FDA guidance on the use of RWE to support regulatory decision-making for medical devices. The program is based on Circles, RegenMed’s patented, technical platform and turnkey process for generating clinical, scientific, and financial value from real-world evidence. The program’s initial Circles will collect and analyze real-world evidence on peripheral neuropathy from dozens of providers in the U.S. In the coming months, the program will grow to include additional pathologies and providers outside of the U.S.
Dr. Phil Harrington
Dr. Phil Harrington, an internationally recognized expert in laser therapies, will be instrumental in developing the program’s clinical surveys and outcomes assessments. Dr. Harrington says, “I am excited to be working with RegenMed in executing the RWE Program. This will help to expand Summus’ clinical and scientific correlations and reach a broader team of providers to collect valuable data.”
Pete Cousins, the COO of Summus Medical Laser
“We look forward to unlocking new frontiers of innovation and patient care through the RWE Program. Collaborating with RegenMed presents an invaluable opportunity to accelerate and push the limits of laser therapy and its capabilities, ultimately advancing medical science and enhancing patient outcomes.”
